Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) has announced that the State Intellectual Property Office of the People’s Republic of China (SIPO) has granted a Chinese patent for the company’s Aequus’ once-weekly transdermal patch containing aripiprazole, in development for treatment of certain psychiatric disorders.
As quoted in the press release:

The patent, granted under No. 201180052667.0, is titled “Aripiprazole compositions and methods for its transdermal delivery”. This patent has been granted in six other major countries or regions, including the US, Russia, Mexico, Japan, Canada and Australia, and is pending in multiple additional territories.
“We continue to globally expand and strengthen our patent portfolio for our once-weekly transdermal aripiprazole program,” said Anne Stevens, COO and Director of Aequus Pharmaceuticals. “This Chinese patent not only secures key elements of our formulation in a significant market, it also expands regional out-licensing and partnering opportunities. This comes at an important time as we accelerate our business development efforts for this program, a key initiative for increasing shareholder value.”
Aequus owns worldwide rights to the formulation described in the issued patent.

Click here to read the full press release.